HerediGene For Providers

Who Should Consider Inhera Hereditary Caner Testing?

The following criteria are common for patients who may be candidates for hereditary cancer testing:

Cancer at a young age
  • Breast cancer ≤45 years
  • Colorectal cancer ≤50 years
  • Endometrial cancer ≤50 years
  • Triple negative breast cancer ≤60 years
Rare cancer/tumor
  • Ovarian cancer
  • Pancreatic cancer
  • Male breast cancer
  • Metastatic prostate cancer
  • Colorectal or endometrial cancer with abnormal IHC tumor staining
  • 10 or more colorectal polyps (especially adenomas)
Multiple cancers (in the patient and/or relatives on one side of the family)
  • Two breast cancers, with one ≤50 years
  • Three breast cancers at any age
  • Three prostate cancers at any age
  • Two or more colorectal, uterine, ovarian, gastric, pancreatic, urinary, biliary, small bowel, or brain cancers
  • Three or more melanomas, especially with a history of pancreatic cancer
  • Breast or prostate cancer plus Ashkenazi Jewish ancestry
Additionally, genetic counselors can help identify patients who are appropriate for Inhera testing.

National Comprehensive Cancer Network Clinical Practice Guidelines

For more information on the latest cancer detection, prevention, and risk reduction guidelines, visit the National Comprehensive Cancer Network resource.
More

The Inhera family of tests look for inherited genetic variants linked to an increased risk for developing certain types of cancer. Inhera results can help you personalize a plan of care for your patients, whether to reduce risk or increase screening and detect cancer at an earlier, more treatable stage.

These tests include full gene sequencing as well as testing of selected genes for large deletions and duplications by MLPA.

Gene Lists

  • Inhera: BRCA1 and 2 
    BRCA1, BRCA2
  • Inhera: Breast and Gynecological Cancer 
    ATM1, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHECK2, EPCAM, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51D, STK11, TP53 
  • Inhera: Lynch Syndrome 
    EPCAM, MLH1, MSH2, MSH6, PMS2
  • Inhera: Colorectal Cancer 
    APC, ATM, BLM, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTE, SMAD4, STK11, TP53 

Our Process

  1. The patient's DNA is extracted from a cheek (buccal) swab or blood sample.
  2. The quality and quantity of DNA is measured before it is tested with Next Generation Sequencing (NGS) technology. This process reads the patient’s DNA sequence for the genes of interest and identifies any changes from the expected sequence.
  3. Detected changes, or variants, are then analyzed to determine whether or not they are clinically significant, and a report is generated listing any important changes we find that may indicate a hereditary risk of developing cancer.
  4. Certain genes are tested with MLPA technology to look for copy number variants (CNVs).
  5. A report identifying either a positive risk for hereditary cancer or a negative* (no increased risk) result will be returned to the ordering provider.

*A negative result can mean that no genetic variants of consequence were detected in the genes tested. However, other family members may still have a genetic variant linked to an increased risk of being diagnosed with a hereditary condition.

Order Inhera

Two ways to order:

  1. If you have iCentra access, place your order via iCentra PowerChart. 
  2. Or, download the order form here and fax the completed form to (435) 251-5781.

Specimen Requirements

Inhera testing is usually performed on a buccal swab specimen, but whole blood is also acceptable. Reference the Test Directory or download this PDF for more information on collection, specimen preparation, storage, and stability.

Sample Report

Your Inhera test results will come as formatted in the sample report below.

Billing and Insurance Information

While some insurance companies cover genetic testing, please work with the patient’s insurance company for any pre-authorization requirements prior to ordering. If you have any questions, or would like assistance, please call our customer service representatives at (435) 251-5780.